Floatz logo

Margetuximab

Hematologic Neoplasms

MacroGenicsmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

137 Active assets in the Hematologic Neoplasms cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Margetuximab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
HER-2 Positive Breast CancerDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →